Fosamax Osteonecrosis of the Jaw Settlement: Criteria Explained

Latest update (2026-05)

FDA enforcement record (Ongoing): This recall is being conducted due to out of specification assay results in a limited number of bottles that were stored on side. [source]

From General Health to Occupational Exposure

The legacy of general health and science information has long served as a foundation for public understanding of medical conditions and their management. Within this broad context, discussions of bone health and pharmaceutical interventions have been standard, emphasizing the importance of informed patient-provider communication. This established framework now provides a necessary backdrop for examining specific exposure scenarios that arise in occupational settings. Transitioning from this general health perspective, attention must be directed toward the particular circumstances of individuals who have had prolonged or high-level exposure to certain medications. In the context of mass production environments, workers may encounter substances or conditions that differ significantly from typical patient experiences. The shift from a general health audience to one focused on occupational exposure requires careful consideration of how routine medical advice translates into workplace realities. Specifically, the concern moves from broad health maintenance to the identification of potential risks associated with sustained contact with pharmaceutical compounds during manufacturing or handling processes. This pivot acknowledges that occupational exposure can introduce variables not fully addressed in standard patient education materials. The focus narrows to understanding how such exposure might relate to specific adverse outcomes, such as those involving bone and jaw health, without making mechanistic claims. This transition sets the stage for a more targeted examination of exposure criteria and their implications.

Understanding Fosamax and Osteonecrosis of the Jaw

Fosamax (alendronate) is a bisphosphonate medication prescribed for the treatment of osteoporosis. A known adverse effect associated with its use is osteonecrosis of the jaw (ONJ), a condition characterized by exposed, non-healing bone in the maxillofacial region. This section outlines the clinical presentation, mechanistic pathways, risk factors, and settlement-related considerations for affected patients, based on provided evidence. Clinical Presentation and Diagnosis: Osteonecrosis of the jaw can occur spontaneously or be triggered by dental procedures. According to FDA-approved labeling, ONJ is 'generally associated with tooth extraction and/or local infection with delayed healing' (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The condition involves exposed bone in the jaw that fails to heal within eight weeks after identification. Diagnosis is primarily clinical, based on visual examination and patient history. Imaging may be used to assess the extent of bone involvement, but no specific laboratory test exists. The time to onset of symptoms after starting Fosamax can vary widely, from 'one day to several months after starting the drug' (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Most patients experience relief after discontinuing the medication, though a subset may have recurrence if rechallenged with the same or another bisphosphonate.

Mechanistic Pathways and Risk Factors

Fosamax (alendronate) works by inhibiting osteoclast-mediated bone resorption, which reduces bone turnover. This mechanism is beneficial for osteoporosis but can lead to adverse effects in the jawbone. Research using animal models has explored the effects of bisphosphonates on jawbone characteristics. In a study of estrogen-deficient rats, treatments with alendronate did not substantially change jawbone properties such as tissue mineral density distribution or nanoindentation characteristics, compared to sham controls (https://pubmed.ncbi.nlm.nih.gov/40345077/). However, the study noted that 'the surface of alveolar bone surrounding teeth showed a trend of more erosion and addition of new bone tissues' in ovariectomized rats (https://pubmed.ncbi.nlm.nih.gov/40345077/). These findings suggest that the jawbone may respond differently to bisphosphonates than other skeletal sites, potentially contributing to ONJ risk. The exact mechanism linking Fosamax to ONJ is not fully understood, but it is believed to involve suppressed bone remodeling, leading to microdamage accumulation and impaired healing after dental trauma or infection. Known risk factors for ONJ include 'invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders (e.g., periodontal and/or other pre-existing dental disease, anemia, coagulopathy, infection, ill-fitting dentures)' (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The risk may increase with longer duration of bisphosphonate exposure. For patients requiring invasive dental procedures, 'discontinuation of bisphosphonate treatment may reduce the risk for ONJ' (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

Settlement Criteria and Legal Considerations

For patients who have developed ONJ after using Fosamax, settlement criteria typically require evidence of a causal link between the drug and the injury. Key factors include a documented timeline of Fosamax use, onset of ONJ symptoms, and exclusion of other causes. The label notes that 'in placebo-controlled clinical studies of FOSAMAX, the percentages of patients with these symptoms were similar in the FOSAMAX and placebo groups' (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56), which may complicate individual claims. However, post-marketing reports have established a recognized association. Patients seeking settlement must demonstrate that their ONJ resulted from Fosamax use, often requiring medical records showing the drug was prescribed and taken, and that ONJ developed within a plausible timeframe. The timeline between exposure and documented harm can vary from days to months after starting the drug. Legal criteria may also consider whether the patient had known risk factors, such as dental procedures or cancer treatment, that could have contributed. The adequacy of warnings regarding Fosamax and ONJ is a key consideration. FDA-approved labeling includes a dedicated section on osteonecrosis of the jaw, describing its association with bisphosphonates and listing risk factors. However, some patients may not have been adequately informed about the potential for ONJ before starting treatment. The label advises discontinuation if severe symptoms develop, but the timing of onset can be unpredictable.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is Fosamax and how is it linked to osteonecrosis of the jaw?

Fosamax (alendronate) is a bisphosphonate used to treat osteoporosis. It has been associated with osteonecrosis of the jaw (ONJ), a condition where jawbone tissue dies and fails to heal. The link is supported by FDA labeling and post-marketing reports, though the exact mechanism is not fully understood.

What are the settlement criteria for Fosamax-related ONJ?

Settlement criteria typically require documented Fosamax use, a confirmed ONJ diagnosis, and evidence of a causal link. Medical records showing the timeline of exposure and onset of symptoms are crucial. Risk factors such as dental procedures or cancer may also be considered.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Fosamax exposure and a confirmed Osteonecrosis of the Jaw diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.